<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix to Present at the William Blair 41st Annual Growth Stock Conference

    May 25, 2021

    Biodesix, Inc. today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021.

    Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021

    May 7, 2021

    Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11.

    Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer

    June 17, 2021

    Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research

    Biodesix Announces First Quarter 2021 Results

    May 11, 2021

    Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter and provided a corporate update.

    Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

    June 4, 2021

    Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

    Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

    September 16, 2021

    Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

    Biodesix Announces

    June 15, 2021

    Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS Cov-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.).

    Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

    August 25, 2021

    Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors.

    First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

    May 26, 2021

     Biodesix, Inc. and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of “Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-Lung).”

    Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time

    April 28, 2021

    Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time. Read more >>
    3 4 5 6 7 8 9 10 11